168910-32-5 Usage
Uses
Used in Pharmaceutical Industry:
5-(4-Tolylthio)-2,4-diaminoquinazoline is used as a modulator of serine/threonine protein kinase function for its potential role in regulating cellular processes and signaling pathways. This makes it a promising candidate for the development of drugs targeting various diseases.
Used in Oncology:
5-(4-Tolylthio)-2,4-diaminoquinazoline is used as an antitumor agent due to its ability to inhibit the growth and proliferation of cancer cells. It may be employed in the development of targeted therapies for various types of cancer.
Used in Fibrotic Disease Treatment:
5-(4-Tolylthio)-2,4-diaminoquinazoline is used as an anti-fibrotic agent, potentially helping to reduce the formation of fibrous tissue and alleviate the symptoms of fibrotic diseases. This application may contribute to the development of treatments for conditions such as liver fibrosis, kidney fibrosis, and pulmonary fibrosis.
Check Digit Verification of cas no
The CAS Registry Mumber 168910-32-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,8,9,1 and 0 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 168910-32:
(8*1)+(7*6)+(6*8)+(5*9)+(4*1)+(3*0)+(2*3)+(1*2)=155
155 % 10 = 5
So 168910-32-5 is a valid CAS Registry Number.
InChI:InChI=1/C15H14N4S/c1-9-5-7-10(8-6-9)20-12-4-2-3-11-13(12)14(16)19-15(17)18-11/h2-8H,1H3,(H4,16,17,18,19)
168910-32-5Relevant academic research and scientific papers
Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds
-
, (2008/06/13)
The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In additi
Selective inhibitors of Candida albicans dihydrofolate reductase: Activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines
Chan,Hong,Kuyper,Baccanari,Joyner,Tansik,Boytos,Rudolph
, p. 3608 - 3616 (2007/10/03)
The recent increase in fungal infections, especially among AIDS patients, has resulted in the need for more effective antifungal agents. In our search for such agents, we focused on developing compounds which inhibit fungal dihydrofolate reductase (DHFR).
